Inactive Instrument
Quotes Oramed Pharmaceuticals, Inc. Xetra
Stocks
OJU
US68403P1049
Biotechnology & Medical Research
|
End-of-day quote
Xetra
|
||
| - EUR | - |
|
| 08-31 | Lifeward Names Josh Hexter as Interim CEO and Rami Aviram as CFO | MT |
| 08-10 | Oramed Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Stock exchange
Xetra
OJU - €
-
0
€
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
| ORMP | 5.070USD | +4.54% | 956K $ | ||
CBOE
| ORMP | 5.080USD | +4.85% | 73.89K $ | |
|
Börse Stuttgart
| OJU1 | 4.365EUR | +5.43% | 17.46K € | |
|
TEL AVIV STOCK EXCHANGE
| ORMP | 1,518.00ILa | -0.65% | 4.52M ILa | |
|
Tradegate
| OJU1 | 4.380EUR | +4.66% | 1.34K € | |
|
Deutsche Boerse AG
| OJU1 | 4.245EUR | -0.24% | 12.74 € | |
|
Boerse Muenchen
| OJU1 | 4.385EUR | +3.79% | 0 € |
Basic data
Market Cap (EUR)
201,747,166
Market Cap (USD)
201,747,166
Net sales (USD)
2,000,000
Free-Float
82.35 %
Free-Float capitalization (EUR)
192,580,889
Free-Float capitalization (USD)
166,139,533
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 0.00% | - | - | 202M | |
| +0.97% | -0.75% | +3.51% | +18.46% | 49.74B | |
| -0.30% | -2.88% | +429.29% | +496.95% | 44.98B | |
| +2.13% | +0.89% | +43.59% | +17.61% | 42.52B | |
| +0.87% | -3.73% | +8.96% | +73.17% | 40.78B | |
| -0.90% | -3.67% | +14.26% | +48.44% | 32.89B | |
| +2.71% | +6.82% | - | - | 17.09B | |
| +1.68% | -4.20% | +25.28% | +116.83% | 16.28B | |
| +1.70% | -0.05% | +18.53% | +28.50% | 14.4B | |
| +3.34% | -1.13% | +80.94% | +39.19% | 13.48B | |
| Average | +1.36% | -1.26% | +78.05% | +104.89% | 27.24B | |
| Weighted average by Cap. | +1.01% | -1.78% | +93.87% | +123.25% |
Historical Quotes: Oramed Pharmaceuticals, Inc.
| Date | Opening | High | Low | Close | Volume | Change |
|---|
Price Extremes
- Stock Market
- Stocks
- ORMP Stock
- OJU Stock
- Quotes Oramed Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
